A new movement in medicine aims to teach “shame competence,” helping physicians recognize and manage one of the field’s most corrosive yet overlooked emotions.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Real-world data show similar rates of severe GI events with semaglutide, dulaglutide, and tirzepatide, reinforcing comparable safety across agents in routine care.
Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.